140 related articles for article (PubMed ID: 35298961)
21. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
22. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
23. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
24. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
25. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity.
Eissa AAM; Aljamal KFM; Ibrahim HS; Abdelrasheed Allam H
Bioorg Chem; 2021 Nov; 116():105318. PubMed ID: 34488123
[TBL] [Abstract][Full Text] [Related]
27. Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity.
Tian C; Yang C; Wu T; Lu M; Chen Y; Yang Y; Liu X; Ling Y; Deng M; Jia Y; Zhou Y
Bioorg Med Chem Lett; 2021 Sep; 48():128271. PubMed ID: 34284105
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-
Sobh EA; Dahab MA; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2220579. PubMed ID: 37288786
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
[TBL] [Abstract][Full Text] [Related]
30. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition.
Yang H; Li Q; Su M; Luo F; Liu Y; Wang D; Fan Y
Bioorg Med Chem; 2021 Sep; 46():116346. PubMed ID: 34403956
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway.
Wang Z; Liu L; Dai H; Si X; Zhang L; Li E; Yang Z; Chao G; Zheng J; Ke Y; Lihong S; Zhang Q; Liu H
Bioorg Med Chem; 2021 Aug; 43():116265. PubMed ID: 34192644
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and biological evaluation of new thieno[2,3-
Elmenier FM; Lasheen DS; Abouzid KAM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):315-332. PubMed ID: 34955086
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy.
Ibrahim TS; Hawwas MM; Taher ES; Alhakamy NA; Alfaleh MA; Elagawany M; Elgendy B; Zayed GM; Mohamed MFA; Abdel-Samii ZK; Elshaier YAMM
Bioorg Chem; 2020 Dec; 105():104352. PubMed ID: 33080494
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
[TBL] [Abstract][Full Text] [Related]
36. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones.
Eldehna WM; Ibrahim HS; Abdel-Aziz HA; Farrag NN; Youssef MM
Eur J Med Chem; 2015 Jan; 89():549-60. PubMed ID: 25462265
[TBL] [Abstract][Full Text] [Related]
38. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition.
Elmeligie S; Aboul-Magd AM; Lasheen DS; Ibrahim TM; Abdelghany TM; Khojah SM; Abouzid KAM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1347-1367. PubMed ID: 31322015
[TBL] [Abstract][Full Text] [Related]
40. Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.
Elbastawesy MAI; Aly AA; Ramadan M; Elshaier YAMM; Youssif BGM; Brown AB; El-Din A Abuo-Rahma G
Bioorg Chem; 2019 Sep; 90():103045. PubMed ID: 31212178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]